Skip to main
BDX

BDX Stock Forecast & Price Target

BDX Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 15%
Hold 54%
Sell 0%
Strong Sell 0%

Bulls say

Becton Dickinson is a financially strong company with a solid track record of revenue growth, margin improvement, shareholder returns and smart capital allocation. Despite facing challenges in some markets, the company's strong earnings in FY2026 and planned launch of new products indicate a positive outlook for continued growth. With a majority of revenue coming from the United States and a focus on increasing shareholder returns, BD is well-positioned for future success.

Bears say

Becton Dickinson is facing headwinds in its Medical, Life Sciences, and Interventional segments, with weaker revenue growth and lower market demand for its products. Additionally, ongoing challenges in China, funding cuts, tariffs, and changing healthcare delivery and reimbursement could negatively impact the company's sales and operations. These risks, coupled with competition from larger and more specialized firms, could hinder BD's ability to achieve its financial targets and create a downside scenario for the stock.

BDX has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 15% recommend Buy, 54% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Becton, Dickinson and Co. (BDX) Forecast

Analysts have given BDX a Buy based on their latest research and market trends.

According to 13 analysts, BDX has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $184.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $184.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Becton, Dickinson and Co. (BDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.